SCHEMBL30983401

SCHEMBL30983401

Cc1cc(OCCN2CCNCC2)ncc1-c1nc2c(OC3(C)CC3)ncnc2n1Cc1cccc(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 12/20 0.41
▸ HTR2A P28223 4/20 0.39
▸ HTR1A P08908 3/20 0.39
▸ HTR7 P34969 3/20 0.39
▸ DRD2 P14416 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ HTR2C P28335 3/20 0.35
▸ PIK3CD O00329 2/20 0.34
▸ HTR2B P41595 2/20 0.34
▸ CHRM4 P08173 1/20 0.33
▸ ADRB1 P08588 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ FPR3 P25089 1/20 0.33
▸ HTR1D P28221 1/20 0.33
▸ HTR1B P28222 1/20 0.33
▸ HTR1E P28566 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983453 0.94 PIK3CD (0.39) HTR6HTR1AHTR7DRD2PIK3CD
SCHEMBL30983872 0.91 PIK3CD (0.39) HTR6HTR1ADRD2PIK3CDHTR1D
SCHEMBL30983394 0.90 PIK3CD (0.39) HTR6HTR1AHTR7PIK3CDSIGMAR1
SCHEMBL31269113 0.89 PIK3CD (0.38) HTR6DRD2PIK3CD
SCHEMBL30983562 0.88 HTR6 (0.39) HTR6HTR2ADRD2ALDH1A1CNR1
SCHEMBL30983378 0.87 HTR6 (0.41) HTR6HTR2AHTR1AHTR7DRD2
SCHEMBL30983871 0.87 PIK3CD (0.41) HTR1AHTR7DRD2PIK3CDHTR1D
SCHEMBL30983537 0.86 PIK3CD (0.40) HTR1AHTR7DRD2PIK3CDHTR1D
SCHEMBL30983552 0.83 PIK3CD (0.40) HTR1AHTR7PIK3CD
SCHEMBL30983363 0.82 HTR1D (0.40) HTR6HTR1ADRD2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR6 4806/4885HTR2A 4458/4885HTR1A 4588/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HTR6 4806/4885HTR2A 4458/4885HTR1A 4588/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR6 4806/4885HTR2A 4458/4885HTR1A 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback